MATK (20.01) is at a price not seen since the depths of the bear market in 2002, which was before the company had established its hegemony in the infant-formula business. MATK was down 3% today, probably due to fallout from the WSJ article. At these levels, it is getting tempting.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”